Last reviewed · How we verify
VVN461 Ophthalmic Solution 0.25%
At a glance
| Generic name | VVN461 Ophthalmic Solution 0.25% |
|---|---|
| Sponsor | VivaVision Biotech, Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VVN461 Ophthalmic Solution 0.25% CI brief — competitive landscape report
- VVN461 Ophthalmic Solution 0.25% updates RSS · CI watch RSS
- VivaVision Biotech, Inc portfolio CI